Table 1.
General patient characteristics
| Characteristic | Invasive breast cancer (n = 36,050) |
Lobular (n = 5135) |
Ductal (n = 28,590) |
|||
|---|---|---|---|---|---|---|
| No MRI (%) | MRI (%) | No MRI (%) | MRI (%) | No MRI (%) | MRI (%) | |
| Year of incidence | ||||||
| 2011 | 8455 (70.4) | 3559 (29.6) | 842 (48.6) | 890 (51.4) | 7044 (73.9) | 2487 (26.1) |
| 2012 | 8586 (70.7) | 3558 (29.3) | 794 (46.1) | 928 (53.9) | 7159 (74.3) | 2472 (25.7) |
| 2013 | 8269 (69.5) | 3623 (30.5) | 725 (43.1) | 956 (56.9) | 6925 (73.5) | 2503 (26.5) |
| Age group (years) | ||||||
| <50 | 3495 (51.6) | 3282 (48.4) | 246 (31.5) | 535 (68.5) | 3046 (54.1) | 2590 (45.9) |
| 50–70 | 13,974 (69.9) | 6023 (30.1) | 1168 (41.0) | 1683 (59.0) | 11,929 (74.6) | 4068 (25.4) |
| 70+ | 7814 (84.5) | 1,435 (15.5) | 947 (63.0) | 556 (37.0) | 6153 (88.4) | 804 (11.6) |
| cT stage | ||||||
| cT1 | 17,156 (73.4) | 6,211 (26.6) | 1407 (49.9) | 1413 (50.1) | 14,663 (76.6) | 4489 (23.4) |
| cT2 | 6164 (62.9) | 3630 (37.1) | 657 (38.7) | 1042 (61.3) | 5036 (67.3) | 2443 (32.7) |
| cT3 | 377 (43.8) | 484 (56.2) | 97 (30.6) | 220 (69.4) | 236 (49.1) | 245 (50.9) |
| cT4 | 158 (75.2) | 52 (24.8) | 17 (56.7) | 13 (43.3) | 128 (78.5) | 35 (21.5) |
| Unknown | 1455 (80.0) | 363 (20.0) | 183 (68.0) | 86 (32.0) | 1065 (81.0) | 250 (19.0) |
| cN stage | ||||||
| cN0 | 22,393 (70.6) | 9316 (29.4) | 2091 (45.8) | 2473 (54.2) | 18,692 (74.5) | 6383 (25.5) |
| cN1–3 | 2575 (66.3) | 1312 (33.8) | 235 (46.6) | 269 (53.4) | 2236 (69.1) | 1002 (30.9) |
| Unknown | 342 (75.3) | 112 (24.7) | 35 (52.2) | 32 (47.8) | 200 (72.2) | 77 (27.8) |
| ER/PR/HER2 status | ||||||
| ER+ or PR+, and HER2− | 18,690 (69.3) | 8276 (30.7) | 2011 (44.0) | 2564 (56.0) | 15,468 (74.3) | 5356 (25.7) |
| ER+ or PR+, and HER2+ | 1829 (67.3) | 890 (32.7) | 95 (48.2) | 102 (51.8) | 1660 (68.3) | 769 (31.7) |
| ER− and PR− and HER2− | 2692 (74.2) | 934 (25.8) | 70 (64.2) | 39 (35.8) | 2356 (74.2) | 818 (25.8) |
| ER− and PR− and HER2+ | 862 (68.5) | 397 (31.5) | 12 (41.4) | 17 (58.6) | 791 (69.3) | 350 (30.7) |
| Unknown | 1237 (83.6) | 243 (16.4) | 173 (76.9) | 52 (23.1) | 853 (83.5) | 169 (16.5) |
| Grade | ||||||
| 1 | 6510 (72.5) | 2476 (27.6) | 368 (42.5) | 498 (57.5) | 5366 (75.1) | 1779 (24.9) |
| 2 | 10,777 (68.1) | 5040 (31.9) | 1591 (45.8) | 1886 (54.2) | 8720 (74.3) | 3024 (25.7) |
| 3 | 7016 (71.7) | 2771 (28.3) | 256 (50.9) | 247 (49.1) | 6,351 (72.7) | 2385 (27.3) |
| Unknown | 1007 (69.0) | 453 (31.0) | 146 (50.5) | 143 (49.5) | 691 (71.6) | 274 (28.4) |
| Multifocality | ||||||
| No | 22,150 (73.5) | 8008 (26.5) | 1854 (48.6) | 1964 (51.4) | 18,764 (76.8) | 5656 (23.2) |
| Yes | 2738 (50.5) | 2688 (49.5) | 453 (36.3) | 796 (63.7) | 2102 (54.2) | 1777 (45.8) |
| Unknown | 422 (90.6) | 44 (9.4) | 54 (79.4) | 14 (20.6) | 262 (90.0) | 29 (10.0) |
| Margin involvement | ||||||
| Yes | 981 (69.4) | 433 (30.6) | 156 (53.2) | 137 (46.8) | 755 (73.8) | 268 (26.2) |
| No | 23,474 (69.8) | 10,166 (30.2) | 2059 (44.3) | 2592 (55.7) | 19,753 (73.5) | 7106 (26.5) |
| Contralateral breast cancer | ||||||
| Yes | 336 (45.7) | 399 (54.3) | 52 (32.3) | 109 (67.7) | 256 (48.7) | 270 (51.3) |
| No | 24,974 (70.7) | 10,341 (96.3) | 2309 (46.4) | 2665 (53.6) | 20,872 (74.4) | 7192 (25.6) |